North Carolina will receive $2.1 million as part of a settlement with Amgen over allegations that the drugmaker illegally promoted two medications, Attorney General Roy Cooper’s office announced Tuesday.
The $71 million settlement includes North Carolina and 48 other states.
Amgen was accused of using a practice called off-label marketing to promote Arenesp and Enbrel, two biologic medications, for purposes that had not been approved by the Food and Drug Administration.
Arenesp is approved to treat certain types of anemia. The company was accused of promoting it for dosing frequencies longer than were approved by the FDA, and of marketing Arenasp for anemia caused by cancer without the required FDA approval.
Sign Up and Save
Get six months of free digital access to The News & Observer
Enbrel is approved to treat several conditions, including certain types of arthritis and chronic and moderate to severe plaque psoriasis. Amgen was accused of promoting it for mild plaque psoriasis.
In addition to the monetary payment, Amgen marketing and sales employees are also banned from preparing materials or submitting supplementary information to drug reference books used by medical professionals.